drugset / Trial / NCT01059591

First Study in Humans With GSK424887

NCT01059591

Phase 1 Completed 26 enrolled GlaxoSmithKline
RandomizedCrossoverDouble-blindBasic science

Summary

This is the first study in Humans with GSK424887 to evaluate what effects, good or bad, the drug has on human health (safety and tolerability) and the amount of drug which gets into the bloodstream and is eliminated from the body (pharmacokinetics). Also the study aims to investigate the penetration of the drug in the human brain by using PET (Positron Emission Tomography) imaging technology

Timeline

Start
2006-05-25
Primary completion
2007-01-25
Completion
2007-01-25

Drugs

EvaluationDrugModalityDoseRoute
Subject GSK424887 Small molecule 2 mg
Subject GSK424887 Small molecule 10 mg
Subject GSK424887 Small molecule 50 mg
Subject GSK424887 Small molecule 100 mg